Discovery and Biological Characterization of PRMT5:MEP50 Protein-Protein Interaction Inhibitors

Abstract

Protein arginine methyltransferase 5 (PRMT5) is a master epigenetic regulator and an extensively validated therapeutic target in multiple cancers. Notably, PRMT5 is the only PRMT that requires an obligate cofactor, methylosome protein 50 (MEP50), to function. We developed compound 17, a novel small molecule PRMT5:MEP50 protein:protein interaction (PPI) inhibitor, after initial virtual screen hit identification and analog refinement. Molecular docking indicated that compound 17 targets PRMT5:MEP50 PPI by displacing MEP50 W54 burial into a hydrophobic pocket of PRMT5 TIM barrel. In vitro analysis indicates IC50 <500 nM for prostate and lung cancer cells with selective, specific inhibition of PRMT5:MEP50 substrate methylation and target gene expression, and RNA-seq analysis suggests that compound 17 may dysregulate TGF-β signaling. Compound 17 provides a proof of concept in targeting PRMT5:MEP50 PPI, as opposed to catalytic targeting, as a novel mechanism of action and supports further preclinical development of inhibitors in this class.

Description
item.page.description.tableofcontents
item.page.relation.haspart
Cite As
Asberry AM, Cai X, Deng X, et al. Discovery and Biological Characterization of PRMT5:MEP50 Protein-Protein Interaction Inhibitors. J Med Chem. 2022;65(20):13793-13812. doi:10.1021/acs.jmedchem.2c01000
ISSN
Publisher
Series/Report
Sponsorship
Major
Extent
Identifier
Relation
Journal
Journal of Medicinal Chemistry
Source
PMC
Alternative Title
Type
Article
Number
Volume
Conference Dates
Conference Host
Conference Location
Conference Name
Conference Panel
Conference Secretariat Location
Version
Author's manuscript
Full Text Available at
This item is under embargo {{howLong}}